AKROMEGALIYA: SOMATOTROPIN GORMONINING PATOFIZIOLOGIK  VA KLINIK TA’SIRI

Hamroqulova Ganjina; Shomurodova Shirin; Hasanov A’zamxon Baxronovich

Authors

Hamroqulova Ganjina Samarqand davlat tibbiyot universiteti Endokrinologiya kafedrasi 2-kurs klinik ordinator
Shomurodova Shirin Samarqand davlat tibbiyot universiteti Endokrinologiya kafedrasi 2-kurs klinik ordinator
Hasanov A’zamxon Baxronovich Samarqand davlat tibbiyot universiteti Endokrinologiya kafedrasi 2-kurs klinik ordinator

Keywords:

akromegaliya, somatotropin (GH), patofiziologiya, metabolik buzilishlar, kardiovaskulyar asoratlar, muskuloskeletal tizim, diagnostika, monitoring

Abstract

Akromegaliya — somatotropin (o‘sish gormoni, GH) ortiqcha ishlab chiqarilishi natijasida yuzaga keladigan surunkali endokrin kasallik bo‘lib, u skelet, mushak va yumshoq to‘qimalarda giperplaziya va gipertrofiya rivojlanishiga olib keladi. Ushbu maqolada akromegaliyaning patofiziologik mexanizmlari, GH ortiqchaligi bilan bog‘liq metabolik buzilishlar va klinik namoyon bo‘lishi tahlil qilinadi. Tadqiqotda somatotropin gormoni oshishi natijasida yuzaga keladigan kardiovaskulyar, muskuloskeletal va metabolik asoratlar ko‘rib chiqilgan. Maqola akromegaliyaning erta aniqlash, diagnostika va bemorlarni monitoring qilishning klinik ahamiyatini yoritadi hamda zamonaviy davolash strategiyalarini taklif qiladi.

References

1. Melmed S. Acromegaly. N Engl J Med. 2006;355:2558–2573.

2. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.

3. Katznelson L., Laws E.R., Melmed S., et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.

4. Melmed S., Casanueva F.F., Klibanski A., et al. Guidelines for acromegaly management: an update. Pituitary. 2009;12:1–12.

5. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–258.